Annex 2

to the Procedure for Conducting Clinical Trials of Medicinal Products and Expert Evaluation of Materials Pertinent to Clinical Trials

**Requirements**

**to informed consent\***

The information to be given to the patient (healthy volunteer) or his legal representative/close relative in writing and orally shall specify:

that the clinical trial involves research;

the objectives of the clinical trial;

the investigational product, including potential adverse reactions, and the probability for inclusion to one of the clinical trial groups;

the clinical trial procedures;

the subject's rights and responsibilities;

the inconveniences to the subject and expected risk and benefit;

when a clinical trial is of non-therapeutic nature;

other types of treatment with or without use of medicinal products that may be prescribed to the subject;

compensation and/or treatment which a subject may expect in the event of trial-related harm to his/her health, including information on the patient’s (volunteer’s) life and health insurance contract with indication of name and location of an insurance company, number and date of the contract conclusion\*\*;

amount and conditions of the anticipated payment to the subject, if any (in addition to the insurance ones);

the anticipated expenses, if any, to the subject for participation in the clinical trial;

that the subject's participation in the clinical trial is voluntary and that the subject may refuse to participate, at any time, without explanations, without penalty or limitations of rights;

rights of representatives of the Center, ethics committee and the sponsor to direct access to information of the subject's source medical documents for verification of clinical trial procedures and/or data and its processing, without violating the confidentiality of the subject;

that the subject or the subject's legal representative will be informed in a timely manner if any new information becomes available that may be relevant to the subject's willingness to continue participation in the clinical trial;

use of the subject’s personal data for conducting this clinical trial in compliance with the Law of Ukraine “On protection of personal data”, in particular: purpose of processing personal data, composition and contents of personal data, holder of patient’s personal data, access of third persons to personal data;

persons to contact for obtaining additional information on the clinical trial and the rights of trial subjects, as well as natural and/or legal entities to contact in the event of trial-related injury to their health;

the circumstances and/or reasons under which the subject's participation in the trial may be terminated;

the duration of the subject's participation in the clinical trial;

the approximate number of subjects involved in the clinical trial.

The subject’s information should be kept secret and processed within the framework of clinical trial in depersonalized format.

Furthermore, informed consent form shall be signed by an investigator who obtains an informed consent and a subject\*\*\*, and in the event of participation of incapacitated subjects who are incapable of giving themselves an informed consent , by the legal representative/close relative.

\* For the benefit of the subject other protocol-specific information should be added to the informed consent.

\*\* Information about the insurance contract and the insurance company (name, address, contact person, phone/fax, email, etc.) shall be completed by a doctor-investigator directly in a health care setting at signing the informed consent by a patient based on the appropriate information from the applicant of a clinical trial.

\*\*\* If children (under age 14) and minors (from 14 to 18 years old) participate in the clinical trial the informed consent of both parents should be obtained. Children under age 14 and minors shall be given an information about the clinical trial according to their capacity of understanding orally and in writing.

A minor patient shall himself/herself sign and date the informed consent.

Information on involvement of children under age 14 and minors in optional form shall be submitted to guardianship authorities in place of permanent residence of such persons.

In case of involvement of incapacitated subjects who are incapable of giving themselves an informed consent the informed consent may be obtained from their legal representative/close relative depending on the nature of a trial. The witness shall sign the informed consent if required.